Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 1.00 |
| ▸ | MTOR | P42345 | 8/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | NEK2 | P51955 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406624 | 0.90 | PIK3CA (1.00) | PIK3CAMTORKDRFLT3GABRG2 | |
| SCHEMBL7900395 | 0.83 | PIK3CA (0.72) | PIK3CAMTORKDRFLT3GABRG2 | |
| SCHEMBL379791 | 0.81 | PIK3CA (0.68) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL767003 | 0.81 | PIK3CA (0.66) | PIK3CAMTORKDRPIK3CDPIK3CB | |
| SCHEMBL406625 | 0.80 | PIK3CA (0.75) | PIK3CAMTORKDRFLT3GABRG2 | |
| SCHEMBL407547 | 0.78 | PIK3CA (1.00) | PIK3CAMTORKDRPIK3CDPIK3CB | |
| SCHEMBL380323 | 0.72 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL5251547 | 0.72 | KDR (1.00) | PIK3CAMTORKDRFLT3GABRG2 | |
| SCHEMBL16588365 | 0.72 | GABRG2 (0.83) | PIK3CAMTORKDRFLT3GABRG2 | |
| SCHEMBL1543439 | 0.71 | PIK3CA (0.74) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | claimed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | claimed |
| EP-2408773-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2012-01-25 | — | — | EP | claimed |
| WO-2010108074-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2010-09-23 | — | — | WO | claimed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729074-B2 | Inhibitors of PI3 kinase | AMGEN INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2408773-A2 | INHIBITORS OF PI3 KINASE | Amgen, Inc (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010108074-A2 | INHIBITORS OF PI3 KINASE | AMGEN INC. (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071474-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885MTOR 23/4885KDR 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.